Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced ...
What Changed in the Ardelyx Price Target The fair value estimate for Ardelyx has been updated from US$11.60 to US$12.30, a shift tied closely to refreshed expectations around Ibsrela’s future revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback